Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies

Ames, Matthew M.; Brauch, Hiltrud B.; Burgues, Octavio; Chen, David; Cox, Nancy J.; Goetz, Matthew P.; Gomez, Henry L.; Gonzalez-Angulo, Ana M.; Ingle, James N.; Kalari, Krishna R.; Kuffel, Mary J.; Miller, Vincent A.; Nakamura, Yusuke; Perou, Charles M.; Ratain, Mark J.; Ross, Jeffrey S.; Safgren, Stephanie L.; Silva, Grace O.; Stephens, Philip J.; Suman, Vera J.; Sun, James X.; Yelensky, Roman

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies

Abstract

Controversy exists regarding the impact of CYP2D6 genotype on tamoxifen responsiveness. We examined loss of heterozygosity (LOH) at the CYP2D6 locus and determined its impact on genotyping error when tumor tissue is used as a DNA source

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Carolina Digital Repository

cdr.lib.unc.edu:pc289s78z

Last time updated on 26/08/2021